表紙
市場調查報告書

經皮血管成形術 (PTA) 末梢藥物釋放型球囊 (DEB) 導管:醫療設備開發平台評估 (2019年)

Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) Catheters - Medical Devices Pipeline Assessment, 2019

出版商 GlobalData 商品編碼 920867
出版日期 內容資訊 英文 157 Pages
訂單完成後即時交付
價格
經皮血管成形術 (PTA) 末梢藥物釋放型球囊 (DEB) 導管:醫療設備開發平台評估 (2019年) Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) Catheters - Medical Devices Pipeline Assessment, 2019
出版日期: 2019年12月18日內容資訊: 英文 157 Pages
簡介

本報告提供經皮血管成形術 (PTA) 末梢藥物釋放型球囊 (DEB) 導管的開發趨勢調查,產品開發、臨床試驗相關資料,核准趨勢,企業、產品的簡介等彙整資料。

第1章 目錄

第2章 簡介

  • PTA末梢DEB導管:概要

第3章 PTA末梢DEB導管:開發中的產品

  • 各開發階段
  • 各地區
  • 各手續種類
  • 各估計核准日
  • 持續中的臨床試驗

第4章 PTA末梢DEB導管:開發企業

  • 企業:各開發階段
  • 產品:各開發階段

第5章 PTA末梢DEB導管:企業、產品概要

  • AnGes Inc
  • AngioCure, Inc.
  • Boston Scientific Corp
  • Cardionovum GmbH
  • Concept Medical Inc
  • Contego Medical LLC
  • eucatech AG
  • Lifetech Scientific (Shenzhen) Co Ltd
  • Lutonix Inc
  • M.A. Med Alliance SA
  • Medtronic plc
  • Micell Technologies Inc
  • Orchestra BioMed Inc
  • Pulsus Medical LLC
  • QT Vascular Ltd
  • QualiMed Innovative Medizinprodukte GmbH
  • SiL Vascular Ltd
  • Spectranetics Corp
  • SurModics Inc
  • Tailored Medical Devices Inc
  • TransMed7 LLC
  • Vascular Nanotransfer Technologies

第6章 PTA末梢DEB導管:產業的最新趨勢

第7章 附錄

目錄
Product Code: GDME0873EPD

GlobalData's Medical Devices sector report, "Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) Catheters - Medical Devices Pipeline Assessment, 2019" provides an overview of Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) Catheters currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) Catheters pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) Catheters under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) Catheters and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) Catheters under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

  • 1.1 List of Tables 6
  • 1.2 List of Figures 9

2 Introduction 10

  • 2.1 Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) Catheters Overview 10

3 Products under Development 11

  • 3.1 Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) Catheters - Pipeline Products by Stage of Development 11
  • 3.2 Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) Catheters - Pipeline Products by Territory 12
  • 3.3 Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) Catheters - Pipeline Products by Regulatory Path 13
  • 3.4 Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) Catheters - Pipeline Products by Estimated Approval Date 14
  • 3.5 Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) Catheters - Ongoing Clinical Trials 15

4 Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) Catheters - Pipeline Products under Development by Companies 16

  • 4.1 Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) Catheters Companies - Pipeline Products by Stage of Development 16
  • 4.2 Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) Catheters - Pipeline Products by Stage of Development 17

5 Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) Catheters Companies and Product Overview 19

  • 5.1 AnGes Inc Company Overview 19
    • 5.1.1 AnGes Inc Pipeline Products & Ongoing Clinical Trials Overview 19
  • 5.2 AngioCure, Inc. Company Overview 21
    • 5.2.1 AngioCure, Inc. Pipeline Products & Ongoing Clinical Trials Overview 21
  • 5.3 Boston Scientific Corp Company Overview 22
    • 5.3.1 Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 22
  • 5.4 Cardionovum GmbH Company Overview 27
    • 5.4.1 Cardionovum GmbH Pipeline Products & Ongoing Clinical Trials Overview 27
  • 5.5 Concept Medical Inc Company Overview 31
    • 5.5.1 Concept Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 31
  • 5.6 Contego Medical LLC Company Overview 34
    • 5.6.1 Contego Medical LLC Pipeline Products & Ongoing Clinical Trials Overview 34
  • 5.7 eucatech AG Company Overview 35
    • 5.7.1 eucatech AG Pipeline Products & Ongoing Clinical Trials Overview 35
  • 5.8 Lifetech Scientific (Shenzhen) Co Ltd Company Overview 36
    • 5.8.1 Lifetech Scientific (Shenzhen) Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 36
  • 5.9 Lutonix Inc Company Overview 39
    • 5.9.1 Lutonix Inc Pipeline Products & Ongoing Clinical Trials Overview 39
  • 5.10 M.A. Med Alliance SA Company Overview 44
    • 5.10.1 M.A. Med Alliance SA Pipeline Products & Ongoing Clinical Trials Overview 44
  • 5.11 Medtronic plc Company Overview 45
    • 5.11.1 Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 45
  • 5.12 Micell Technologies Inc Company Overview 49
    • 5.12.1 Micell Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 49
  • 5.13 Orchestra BioMed Inc Company Overview 50
    • 5.13.1 Orchestra BioMed Inc Pipeline Products & Ongoing Clinical Trials Overview 50
  • 5.14 Pulsus Medical LLC (Inactive) Company Overview 51
    • 5.14.1 Pulsus Medical LLC (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 51
  • 5.15 QT Vascular Ltd Company Overview 52
    • 5.15.1 QT Vascular Ltd Pipeline Products & Ongoing Clinical Trials Overview 52
  • 5.16 QualiMed Innovative Medizinprodukte GmbH Company Overview 56
    • 5.16.1 QualiMed Innovative Medizinprodukte GmbH Pipeline Products & Ongoing Clinical Trials Overview 56
  • 5.17 SiL Vascular Ltd Company Overview 57
    • 5.17.1 SiL Vascular Ltd Pipeline Products & Ongoing Clinical Trials Overview 57
  • 5.18 Spectranetics Corp Company Overview 58
    • 5.18.1 Spectranetics Corp Pipeline Products & Ongoing Clinical Trials Overview 58
  • 5.19 SurModics Inc Company Overview 65
    • 5.19.1 SurModics Inc Pipeline Products & Ongoing Clinical Trials Overview 65
  • 5.20 Tailored Medical Devices Inc Company Overview 72
    • 5.20.1 Tailored Medical Devices Inc Pipeline Products & Ongoing Clinical Trials Overview 72
  • 5.21 TransMed7 LLC Company Overview 73
    • 5.21.1 TransMed7 LLC Pipeline Products & Ongoing Clinical Trials Overview 73
  • 5.22 Vascular Nanotransfer Technologies Company Overview 74
    • 5.22.1 Vascular Nanotransfer Technologies Pipeline Products & Ongoing Clinical Trials Overview 74

6 Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) Catheters - Recent Developments 76

  • 6.1 Nov 22, 2019: Medtronic receives FDA approval for IN.PACT AV DCB 76
  • 6.2 Nov 19, 2019: Medtronic reports second quarter financial results for the year 2019 76
  • 6.3 Nov 14, 2019: Medtronic highlights leadership in inclusion, diversity, and equity in 2019 integrated performance report 79
  • 6.4 Nov 12, 2019: Cardiovascular Systems announces Stephen Stenbeck joins Board of Directors 80
  • 6.5 Nov 12, 2019: Cook Medical's leadership updates in Asia-pacific reinforce focus on growth and physician relationships 80

7 Appendix 154

  • 7.1 Methodology 154
  • 7.2 About GlobalData 157
  • 7.3 Contact Us 157
  • 7.4 Disclaimer 157

List of Tables

  • Table 1: Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) Catheters - Pipeline Products by Stage of Development
  • Table 2: Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) Catheters - Pipeline Products by Territory
  • Table 3: Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) Catheters - Pipeline Products by Regulatory Path
  • Table 4: Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) Catheters - Pipeline Products by Estimated Approval Date
  • Table 5: Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) Catheters - Ongoing Clinical Trials
  • Table 6: Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) Catheters Companies - Pipeline Products by Stage of Development
  • Table 7: Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) Catheters - Pipeline Products by Stage of Development
  • Table 8: AnGes Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 9: NF-kB Decoy Oligo Coated PTA Balloon Catheter - Product Status
  • Table 10: NF-kB Decoy Oligo Coated PTA Balloon Catheter - Product Description
  • Table 11: AngioCure, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 12: AngioCure TOP-C Smart Balloon Catheter - Product Status
  • Table 13: AngioCure TOP-C Smart Balloon Catheter - Product Description
  • Table 14: Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
  • Table 15: Ranger Drug-Coated Balloon - Product Status
  • Table 16: Ranger Drug-Coated Balloon - Product Description
  • Table 17: Boston Scientific Corp - Ongoing Clinical Trials Overview
  • Table 18: Ranger Drug-Coated Balloon - A Randomized Trial Comparing Drug-coated Balloon and Regular Balloon for Dialysis Access Stent Graft Restenosis
  • Table 19: Ranger Drug-Coated Balloon - Clinical Study of the Boston Scientific Paclitaxel-coated PTA (Percutaneous Transluminal Angioplasty) Balloon Catheter (Ranger and Ranger SL (OTW) DCB) in China
  • Table 20: Ranger Drug-Coated Balloon - JETStream AtheRectomy with Adjunctive Paclitaxel-coated Balloon Angioplasty Versus Balloon Angioplasty Followed by Paclitaxel-coated Balloon in Treating Complex Denovo Femoropopliteal Arterial Disease: JET-RANGER
  • Table 21: Ranger Drug-Coated Balloon - Prospective, Randomized, Multi-center Study for the Treatment of Subjects with Symptomatic Femoropopliteal Artery Disease with the Ranger Paclitaxel Coated PTA Balloon Catheter (Study Arm) Versus the IN.PACT Drug Eluting Balloon (Control Arm)
  • Table 22: Ranger Drug-Coated Balloon - Prospective, Randomized, Multicenter Clinical Study of the Hemoteq Ranger Paclitaxel-coated PTA Balloon Catheter (Ranger DCB) in Comparison to Uncoated PTA Balloons in Femoropopliteal Lesions
  • Table 23: Ranger Drug-Coated Balloon - RANGER II SFA: A 3:1 Randomized Trial Comparing the Boston Scientific RANGER Paclitaxel Coated Balloon Versus Standard Balloon Angioplasty for the Treatment of Superficial Femoral Arteries (SFA) and Proximal Popliteal Arteries (PPA)
  • Table 24: Cardionovum GmbH Pipeline Products & Ongoing Clinical Trials Overview
  • Table 25: APERTO OTW - Product Status
  • Table 26: APERTO OTW - Product Description
  • Table 27: Cardionovum GmbH - Ongoing Clinical Trials Overview
  • Table 28: APERTO OTW - A Randomized Trial of Aperto Paclitaxel Eluting Dilatation Catheter Compared to POBA in Dialysis Fistula
  • Table 29: Concept Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 30: MagicTouch PTA Balloon Catheter - Product Status
  • Table 31: MagicTouch PTA Balloon Catheter - Product Description
  • Table 32: Concept Medical Inc - Ongoing Clinical Trials Overview
  • Table 33: MagicTouch PTA Balloon Catheter - A Pilot Study to Evaluate the Safety and Efficacy of MagicTouch PTA Sirolimus Coated Balloon for the Treatment of Below-the-Knee (BTK) Lesions
  • Table 34: Contego Medical LLC Pipeline Products & Ongoing Clinical Trials Overview
  • Table 35: Tibial Artery Drug Eluting Balloon - Product Status
  • Table 36: Tibial Artery Drug Eluting Balloon - Product Description
  • Table 37: eucatech AG Pipeline Products & Ongoing Clinical Trials Overview
  • Table 38: Support - Product Status
  • Table 39: Support - Product Description
  • Table 40: Lifetech Scientific (Shenzhen) Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 41: FemFlow Drug-Eluting Peripheral Balloon Catheter (DEB) - Product Status
  • Table 42: FemFlow Drug-Eluting Peripheral Balloon Catheter (DEB) - Product Description
  • Table 43: Lifetech Scientific (Shenzhen) Co Ltd - Ongoing Clinical Trials Overview
  • Table 44: FemFlow Drug-Eluting Peripheral Balloon Catheter (DEB) - Safety and Efficacy Study of FemFlow Drug-eluting Peripheral Balloon Catheter for Lesions with Femoral-popliteal Artery Stenosis or Occlusion: A Prospective, Multi-center, Objective Performance Criteria Clinical Trial
  • Table 45: Lutonix Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 46: Lutonix 014 Drug Coated Balloon PTA Catheter - Product Status
  • Table 47: Lutonix 014 Drug Coated Balloon PTA Catheter - Product Description
  • Table 48: Lutonix 018 Drug Coated Balloon PTA Catheter - Product Status
  • Table 49: Lutonix 018 Drug Coated Balloon PTA Catheter - Product Description
  • Table 50: Lutonix Inc - Ongoing Clinical Trials Overview
  • Table 51: Lutonix 014 Drug Coated Balloon PTA Catheter - A Prospective, Multicenter, Single Arm Real-world Registry Investigating the Clinical Use and Safety of the Lutonix Drug Coated Balloon Percutaneous Transluminal Angioplasty (PTA) Catheter for Treatment of Below-the-Knee (BTK) Arteries
  • Table 52: Lutonix 014 Drug Coated Balloon PTA Catheter - A Prospective, Multicenter, Single Blind, Randomized, Controlled Trial Comparing the Lutonix Drug Coated Balloon Versus Standard Balloon Angioplasty for Treatment of Below-the-knee (BTK) Arteries: Lutonix BTK Trial
  • Table 53: Lutonix 014 Drug Coated Balloon PTA Catheter - Tack Optimized Balloon Angioplasty Study for Superficial Femoral and Proximal Popliteal Arteries Using the Tack Endovascular System
  • Table 54: Lutonix 018 Drug Coated Balloon PTA Catheter - Drug Eluting Balloon for Early Fistula Failure Trial
  • Table 55: M.A. Med Alliance SA Pipeline Products & Ongoing Clinical Trials Overview
  • Table 56: SELUTION Sirolimus Coated Balloon - Product Status
  • Table 57: SELUTION Sirolimus Coated Balloon - Product Description
  • Table 58: Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 59: IN.PACT Admiral DEB - BTK - Product Status
  • Table 60: IN.PACT Admiral DEB - BTK - Product Description

List of Figures

  • Figure 1: Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) Catheters - Pipeline Products by Stage of Development
  • Figure 2: Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) Catheters - Pipeline Products by Territory
  • Figure 3: Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) Catheters - Pipeline Products by Regulatory Path
  • Figure 4: Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) Catheters - Pipeline Products by Estimated Approval Date
  • Figure 5: Percutaneous Transluminal Angioplasty (PTA) Peripheral Drug Eluting Balloons (DEB) Catheters - Ongoing Clinical Trials